| Developers: | Shvabe |
| Branches: | Pharmaceuticals, medicine, healthcare |
2021: Schwabe began to supply devices for the treatment of jaundice in infants abroad
In early October 2021, it became known that the Schwabe holding began to supply devices for the treatment of jaundice in infants abroad through the use of high-intensity, constant and uniform therapeutic light of the narrow therapeutic spectrum 450-480 nm. We are talking about a fibrooptic system for phototherapy called BiliFlex, which was delivered to a Greek hospital.
 | We continue to increase the volume of exports of medical equipment, including strengthening cooperation with Greece. Previously, we supplied neonatal irradiators to this country, also intended for the treatment of jaundice in infants, "said the Director General of the Ural Optical and Mechanical Plant (UOMZ; enterprise is developing a device) Anatoly Sludnykh, whose words are quoted by the Rostec press service. |  |
According to the developers of BiliFlex, effectively and quickly reduces the level of bilirubin in newborns. Moreover, during the procedure, you can hold the baby in your arms. The system may also be used in conjunction with an incubator or heater.
The device is equipped with a timer with a shutdown function at the end of the phototherapy session and an overheating protection system. It is claimed that the device meets the requirements of the methodological recommendations of the Russian Association of Perinatal Medicine Specialists. The device lacks potentially harmful ultraviolet and infrared radiation, which reduces the risk of damage to the skin and eyes of the child and treating doctors, as well as the risk of hyperthermia and dehydration.
In addition to Greece, OOMZ began shipping neonatal equipment to Mongolia, Senegal and Estonia, and also registered a neonatal incubator in Malaysia. By October 2021, the plant is actively working to expand the geography of supplies and the presence in foreign markets.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |